Sunday 11 October 2026 Export all EQ data to Excel Powerpack

Equillium, Inc.

EQ Healthcare Biotechnology

Equillium, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $41.1 million, up 13.9% from fiscal 2023. In the quarter to June 2026, revenue fell 52.3%, EPS grew 75.0% and free cash flow fell 38.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years, revenue growth for three.

1.41 0.03 −2.08%
Market cap
$91.3M
P/E
0.0×
Fwd P/E
−5.2×
Dividend yield
—
F-score
3/9
Altman Z
−6.75
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(90.24%) (93.99%) (54.39%) (58.98%)
ROA
(70.81%) (77.92%) (47.75%) (50.68%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(79.64%) (79.23%) (32.22%) (32.34%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.35) (0.40) (0.20) (0.18)
Free Cash Flow
(22.92) (22.78) (18.91) (20.08)
Other line items

Show all line items

Columns are period end dates